Los Angeles-based NeuroSigma, Inc. has completed a significant investment of approximately $1 million to enhance the manufacturing capabilities of its innovative ADHD treatment device. This funding is directed towards establishing a high-volume manufacturing line in collaboration with Singapore-based Armstrong Asia, aimed at preparing for the launch of the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device in the first quarter of 2026.
The investment is part of a broader strategy following the successful pilot commercialization of the first-generation Monarch eTNS device, which was announced in November 2025. According to the company, the pilot program demonstrated strong market demand, prompting the development of the upgraded version of the device, which is designed specifically for pediatric patients with attention-deficit/hyperactivity disorder (ADHD).
Colin Kealey, president and chief executive officer of NeuroSigma, stated, “This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device. As we move into 2026, we look forward to working with Armstrong Asia to deliver this innovative product to patients and families throughout the world.”
The Monarch eTNS system previously made history as the first wearable medical device to receive FDA clearance as a non-drug treatment option for ADHD. The upcoming second-generation device will retain the core functionality of trigeminal nerve stimulation while offering a simplified user interface to enhance accessibility for families and healthcare providers.
Strategic Collaboration and Market Potential
The collaborative effort between NeuroSigma and Armstrong Asia, supported by Checkmate Capital, emphasizes cross-border transactions within the life sciences and medical technology sectors. Tom Paschall, chief executive of Checkmate Capital and director of NeuroSigma, highlighted the positive outlook for the external neurostimulation sector, stating, “The Monarch eTNS device is a groundbreaking neuro-electronic product that provides patients, families, and physicians with an alternative to stimulant medications and the negative side effects associated with them.”
The funding and manufacturing initiative is not only a step towards expanding NeuroSigma’s production capabilities but also reflects the growing interest in non-invasive treatment options for ADHD. As the company gears up for the launch, it aims to address the needs of a significant demographic that seeks alternatives to traditional stimulant medications.
This investment signifies a critical move in the evolving landscape of ADHD treatment, aligning with NeuroSigma’s commitment to providing innovative solutions for patients and their families.
In conclusion, with the second-generation Monarch eTNS device set to launch in early 2026, NeuroSigma is positioned to make a notable impact in the ADHD treatment market, enhancing the lives of many while fostering advancements in medical technology.